Strong Value proposition for a low dose, weekly, contraceptive patch.

   Evra^® validated market need & convenience segment
   one-third of women have used contraceptive patch
   Simple and strong value proposition - "don't need to take a pill every day"
   Straight forward clinical target - low dose OC labeling


Research Validating AG200-15's Market Potential

With 105 OBGYNs
   89% of OBGYNs likely to prescribe AG200-15
   48% of OBGYNs will begin prescribing immediately
   For an average of 14.9% of their patients requiring contraception

With 1500 Women desiring contraception
   up to 65% of women would speak to their doctor
   up to 77% of women would seek additional information